Qiagen wins FDA clearance for first QIAstat-Dx bloodstream infection panel
QGEN•FDA clearance for first bloodstream infection panel
Qiagen won U.S. FDA clearance for its first QIAstat-Dx bloodstream infection test, the BCID GPF Plus AMR Panel.
The panel identifies gram-positive bacterial or fungal targets, a pan gram-negative target, antimicrobial resistance markers from positive blood cultures in about one hour.
Clearance expands the QIAstat-Dx U.S. menu into bloodstream infections; a gram-negative BCID GN Plus AMR Panel remains under FDA review.
